Management peculiarities of patients with hyperprolactinemia in case of mass formations of the hypothalamic-pituitary region: a clinical case
https://doi.org/10.15829/2713-0177-2023-4-28
Abstract
Hyperprolactinemia is a condition characterized by persistently elevated blood prolactin level. The most prominent manifestations of it are reproductive dysfunction, as well as fat and carbohydrate metabolism disorders, including body weight gain, dyslipidemia, impaired glucose tolerance, and insulin resistance. We describe here a case of hyperprolactinemia in a young man and perform differential diagnosis of prolactinoma with craniopharyngioma. The article demonstrates that initiation of treatment with dopamine agonists allows us to make a correct diagnosis and to determine optimal tactic of management – either therapy or surgery.
About the Authors
T. M. Frolova
Endocrinology Research Centre
Russian Federation
Russian Federation
Tatyana M. Frolova – resident, MD
Moscow
S. Yu. Vorotnikova
Endocrinology Research Centre
Russian Federation
Russian Federation
Svetlana Yu. Vorotnikova – Cand. Sci. (Med.)
Moscow
A. S. Shutova
Endocrinology Research Centre
Russian Federation
Russian Federation
Aleksandra S. Shutova – postgraduate student, endocrinologist
Moscow
L. K. Dzeranova
Endocrinology Research Centre
Russian Federation
Russian Federation
Larisa K. Dzeranova – D. Sci. (Med.)
Moscow
References
1. Рымар О.Д., Воевода С.М., Шахтшнейдер Е.В., и др. Частота метаболического синдрома и его отдельных компонентов у женщин 25–45 лет в зависимости от уровня пролактина. Ожирение и метаболизм. 2021;18(2):180-189. doi: 10.14341/omet12475.
2. Wang AT, Mullan RJ, Lane MA, et al. Treatment of hyperprolactinemia: A system-aticreview and meta-analysis. Syst Rev. 2006;1(1):1-12. doi: 10.1186/2046-4053-1-33.
3. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi: 10.1210/jc.2010-1692.
4. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65(2):265-273. doi: 10.1111/j.1365-2265.2006.02562.
5. Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med. 1977;296(11):589-600. doi: 10.1056/NEJM197703172961103.
6. Bloomgarden E, Molitch ME. Surgical treatment of prolactinomas: cons. Endocrine. 2014;47(3):730-3. doi: 10.1007/s12020-014-0369-9.
7. Korkmaz FN, Gökçay Canpolat A, Şahi̇n M, Çorapçioğlu D. Determination of the frequency of hyperprolactinemia-related etiologies and the etiology-specific mean prolactin levels. Minerva Endocrinol. 2021. doi: 10.23736/S2724-6507.21.03386-8.
8. Hermann LM. Endocrine Reviews. 2014;35(3): 513–543. doi:10.1210/er.2013-1115.
9. Астафьева Л.И., Клочкова И.С., Калинин П.Л., и др. Ожирение и кахексия в качестве первых проявлений папиллярной краниофарингиомы. Ожирение и метаболизм. 2018;15(1):43-49. doi: 10.14341/OMET2018143-49.
10. Woodside B. Prolactin and the hyperphagia of lactation. Physiol Behav. 2007;91(4):375-82. doi: 10.1016/j.physbeh.2007.04.015.
11. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006;17(3):110-6. doi: 10.1016/j.tem.2006.02.005.
12. Романцова Т.И. Репродукция и энергетический баланс: интегративная роль пролактина. Ожирение и метаболизм. 2014;11(1):5-18. doi: 10.14341/omet201415-18.
13. Kirsch P, Kunadia J, Shah S, Agrawal N. Metabolic effects of prolactin and the role of dopamine agonists: A review. Front Endocrinol (Lausanne). 2022; 30:13:1002320. doi: 10.3389/fendo.2022.1002320.
14. Мельниченко Г.А., Марова, Е.И., Романцова Т.И., и др. Результаты длительного наблюдения за больными с умеренной гиперпролактинемией. Проблемы Эндокринологии. 2002;48(3):18-22. doi: 10.14341/probl11608.
15. Colao A, Sarno AD, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148(3):325-31. doi: 10.1530/eje.0.1480325.
16. Pereira-Lima JF, Leães CG, Freitas Neto FM, et al. Hyperprolactinemia and body weight: prevalence of obesity and overweight in patients with hyperprolactinemia. Res J Endocrinol Metab. 2013;1:2. doi: 10.7243/2053-3640-1-2.
17. Clark AJ, Cage TA, Aranda D, et al. Treatment-related morbidity and the management of pediatric craniopharyngioma: a systematic review. J Neurosurg Pediatr. 2012;10(4):293-301. doi: 10.3171/2012.7.PEDS11436.
18. Gan HW, Bulwer C, Jeelani O, et al. Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1. Int J Pediatr Endocrinol. 2015(1):15. doi: 10.1186/s13633-015-0011-5.
19. Kharb S, Pandit A, Garg MK, Brar KS. Rapid improvement in visual field with cabergoline in suprasellar tumor in a young adult: Clinical dilemma solved and surgery averted. Indian J Endocrinol Metab. 2012;16(6):1052-3. doi: 10.4103/2230-8210.103043.
20. Дзеранова Л.К., Федорова Н.С., Воротникова С.Ю., Пигарова Е.А. Описание клинических портретов пациентов с гиперпролактинемией. Ожирение и метаболизм. 2018;15(3):65-69. doi: 10.14341/omet9866.
21. Астафьева Л.И. Клинико-морфологические особенности и результаты медикаментозного и хирургического методов лечения пролактинсекретирующих макроаденом гипофиза. 2012; Автореф. дис. д. м. н.
Review
For citations:
Frolova T.M., Vorotnikova S.Yu., Shutova A.S., Dzeranova L.K. Management peculiarities of patients with hyperprolactinemia in case of mass formations of the hypothalamic-pituitary region: a clinical case. FOCUS. Endocrinology. 2023;4(4):64-69. (In Russ.) https://doi.org/10.15829/2713-0177-2023-4-28
Views:
283
Email this article 